

# Swiss Opportunity Fund


## FACT SHEET January 2020 / PERFORMANCE 0%

After a strong performance in December with a Christmas rally carrying markets to new highs, the new year started where the old left off. This was surprising considering the tension between the US and Iran at the beginning of the new year. Stocks quickly rebounded from their initial losses triggered by the killing of the Iranian general Soleimani in a US drone strike and Iran's retaliatory missile attacks on US military bases in Iraq as it became clear that the US was not planning a military counterattack. New record highs were then set midway through the month, with tailwind coming from the Phase 1 trade deal between the US and China. In this initial trade deal, China agreed to purchase large amounts of US goods and made concessions on foreign access to its financial services markets as well as on intellectual property, forced technology transfers and currency policy. However, since many other topics still need to be negotiated in a Phase 2 deal, the current situation is more like a temporary ceasefire than an actual end to the trade war. Markets were unable to defend their new record highs after the sudden outbreak of the coronavirus. The growing death toll from the virus forced Chinese officials to take drastic action and it has become increasingly obvious that this epidemic will have a negative impact on the larger economy.

The total Swiss market (SPI TR) inched 0.26% higher in January while the mid and small-cap index (SPI Extra TR) was unchanged. The Swiss Opportunity Fund ended the month also with 0 %, matching the benchmark performance. Performance drivers were Zur Rose (+11.4%), Sonova (+9.16%), Galenica (+9.94%) and SPS (+5.27%), while Dufry (-12.8%) led the list of losing stocks due to all the worries about the coronavirus.


What is our current market outlook? As mentioned in our previous monthly update, we see limited upside potential from the current high valuation levels. A lot of positive news has already been priced into the stock market and a consolidation is very likely. The coronavirus can become an additional drag on the market depending on how far and fast it spreads, but this would ultimately be an only temporary factor. Our confidence in the stock market remains intact from a mid-term perspective. As long as the economy keeps growing and there is no sign of a recessionary slowdown or a steep downturn in economic activity, stock markets are likely to continue heading north, regardless of the occasional setback.

## NET-PERFORMANCE SINCE 30.06.2017 (VS SPIEX )




# Swiss Opportunity Fund

## LARGEST POSITIONS



## ALLOCATION BY SECTORS



Total Net Asset Value	CHF mn	66.57
Degree of Investment		95.86%
Net Asset Value per share	CHF	274.32
Last dividend payout	12.03.13	gross 0.92
	18.03.15	gross 1.6
	21.03.18	gross 1.2

## FUND DESCRIPTION

The Swiss Opportunity Fund is an actively managed Swiss equity fund. It invests primarily in the shares of small and mid-cap companies whose main office and/or core business activities are in Switzerland. Investing in the fund gives investors exposure to the Swiss stock market. The Swiss Opportunity Fund's investment objective is to achieve an excess performance versus its benchmark, the SPI Extra TR stock index. Its portfolio structure can diverge significantly from the benchmark's, depending on the current and prospective opportunities associated with specific company developments, stock valuations or the macroeconomic cycle. If we are anticipating a downturn in economic activity, the fund's investments will include stocks with a defensive profile. In an environment of favorable economic conditions, the fund invests primarily in small and mid-cap stocks with the potential to outperform defensive blue chips due to their growth, dynamic qualities and flexibility. When selecting individual investments, we prefer companies with a consistently strong track record in regard to senior management, balance sheet structure and market position. The strategy is long-term in nature and geared towards steady value appreciation.

**DISCLAIMER:** This document is promotional material. This document does not constitute and should not be construed as an offer, or solicitation of an offer, to buy or sell any securities or other financial instruments or to engage in any other investment transaction. Shares of the investment fund described herein, the Swiss Opportunity Fund (the "Fund"), may be offered solely on the basis of the information and representations expressly set forth in the relevant confidential Prospectus ("Fondsvertrag"), and no other information or representations may be relied upon in connection with the offering of the shares. No investment in the Fund may be made or will be accepted save on the basis of the aforementioned Prospectus ("Fondsvertrag"). While every effort has been made to ensure the accuracy of the information contained herein, it may not be relied upon as such and no representations, express or implied, are made as to the completeness, accuracy or timeliness of the information. The price and value of investments as well as any income derived from them may fluctuate. Past performance is not necessarily an indication of future performance, future returns are not guaranteed, and a loss of original capital may occur, including a permanent and unrecoverable loss. These performance data do not take account of commissions and costs incurred on the issue and redemption of units. The investments discussed herein may be unsuitable for investors depending on their specific investment objectives and financial position as well as on the laws of the countries of their citizenship, residence, incorporation or domicile. Investors must independently evaluate each particular investment product in light of their own objectives, risk profile and circumstances and seek, where appropriate, professional advice including tax advice. The information contained in this document should not be deemed to constitute the provision of financial, investment or other professional advice in any way. The fund may not be marketed, either directly or indirectly, in the United States of America or be sold to US persons. Prospectuses ("Fondsvertrag") including regulations, as well as annual and semi-annual reports of the fund are available free of charge from the fund management company LB(Swiss) Investment AG, Claridenstrasse 20, CH-8002 Zürich and using [www.lbswiss.ch](http://www.lbswiss.ch). For German investors the relevant documentations can be obtained free of charge at the information office in Germany (ODDO BHF Aktiengesellschaft, Bockenheimer Landstr. 10, D-60323 Frankfurt am Main) in paper form or electronically at [www.fundinfo.com](http://www.fundinfo.com).

## PERFORMANCE

Performance	SOF	SPIEX	Difference
January	0.00%	0.01%	-0.01%
2020 YTD	0.00%	0.01%	-0.01%
2019	30.07%	30.42%	-0.35%
2018	-18.01%	-17.23%	-0.78%
2017	26.40%	29.73%	-3.33%
2016	6.56%	8.50%	-1.94%

Performance	SOF	SPIEX	Difference
12 months	19.48%	19.49%	-0.01%
3 yrs p.a.	9.35%	11.12%	-1.77%
5 yrs p.a.	9.86%	12.65%	-2.79%

## STATISTICS

over 3 years	SOF	SPIEX
Risk Ratio p.a.	12.10	12.58
Tracking Error	2.33	
Information ratio	-0.75	
Alpha	-1.12	
Sharpe Ratio	0.80	0.91

## FUND FACTS

Fund Domicile	Switzerland
Investment Manager	Santro Invest SA, Pfäffikon/SZ
Custodian Bank	Bank J. Safra Sarasin AG, Basle
Administrator	LLB Swiss Investment AG, Zurich
Date of Inception	July 1, 2005
Fund Currency	CHF
Reporting Period	Calendar Year
Issuance / Redemption	Daily
Swiss Sec. Number / ISIN	2.177.802 / CH0021778029

## COSTS

Management Fee	1.25% p.a
Performance Fee	10% of the OP vs SPIEX
Redemption Fee	None
Total Expense Ratio (TER)	1.43% p.a. (as per 31.12.2018)